

CORRECTION

Open Access

TRizol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis

Amelie Fassbender, Peter Simsa, Cleophas M Kyama, Etienne Waelkens, Attila Mihalyi, Christel Meuleman, Olivier Gevaert, Raf Van de Plas, Bart de Moor and Thomas M D'Hooghe^{1,2,3,4*}

Since publication of our article [1], we have realised that we did not include the full data in Table 1 and missed the word (TOF) in the result/discussion section. We have provided here the adapted sentence and another version of the table, including all the information intended.

Results/Discussion

“Therefore, we plan to repeat this study in a larger sample size including well defined endometrial samples obtained during menstrual, follicular and secretory phase, to validate the reproducibility of SELDI-TOF MS technology in these samples and to identify the protein

Table 1 The representative molecular weights of the proteins identified in the mRNA Microarray study [Thirteen] [2]

Protein	Mass in Da
Osteoglycin (OGN/4969)	33,922
Interleukin-6 signal transducer (IL6ST/3572)	isoform 1 103,537 isoform 2 37,499
Cytochrome P450, Family 2, Subfamily J, polypeptide 2 (CYP2J2/1573)	57,611
Carboxypeptidase E (CPE/1363)	53,151
Fibronectin 1 (FN1/2335)	different isoforms 1. 262,607 2. 71,943 3. 259,198 4. 222,944 5. 243,316 6. 240,477 7. 268,894 8. 252,793 9. 246,670 10. 239,608 11. 262,388 12. 221,274 13. 249,304 14. 249,384

* Correspondence: thomas.dhooghe@uzleuven.be

¹Leuven University Fertility Centre, Department of Obstetrics & Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium

Full list of author information is available at the end of the article

Table 1 The representative molecular weights of the proteins identified in the mRNA Microarray study [Thirteen] [2] (Continued)

	15. 272,302
Synuclein, gamma (SNCG/6623)	13,331
BAI1-associated protein 2 (BAIAP2/10458)	different isoforms
	1. 60,868
	2. 59,014
	3. 56,626
	4. 57,359
	5. 57,445
	6. 57,430
Protocadherin 17 (PCDH17/27253)	different isoforms
	1. 126,229
	2. 96,570
Protein tyrosine phosphatase, receptor type, R (PTPRR/5801)	Alpha 73,834 Da Gamma 46,581 Da Delta 51,046 Da

peaks observed after proteomic analysis, which are expensive and labour intense requiring High-performance liquid chromatography or high-pressure liquid chromatography (HPLC) and matrix assisted laser desorption ionization Time-of-Flight-Mass Spectrometry (MALDI-TOF/TOF MS).”

Author details

¹Leuven University Fertility Centre, Department of Obstetrics & Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium. ²Division of Reproductive Health and Biology, Institute of Primate Research, P.O. Box 24481-00502 Karen, Nairobi, Kenya. ³Biochemistry Section, Department of Molecular Cell Biology, Campus Gasthuisberg, Leuven, Belgium. ⁴Department of Electrical Engineering, ESAT-SCD, K.U.Leuven, Kasteelpark-Arenberg 10, B-3001 Heverlee, Belgium.

Received: 29 March 2011 Accepted: 6 April 2011 Published: 6 April 2011

References

1. Fassbender Amelie, Simsa Peter, Kyama MCleophas, Waelkens Etienne, Mihalyi Attila, Meuleman Christel, Gevaert Olivier, Van de Plas Raf, de Moor Bart, D'Hooghe MThomas: **TRIZol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis.** *Reproductive Biology and Endocrinology* 2010, **8**:123.
2. Sherwin JR, Sharkey AM, Mihalyi A, Simsa P, Catalano RD, D'Hooghe TM: **Global gene analysis of late secretory phase, eutopic endometrium does not provide the basis for a minimally invasive test of endometriosis.** *Hum Reprod* 2008, **23**(5):1063-1068.

doi:10.1186/1477-7827-9-44

Cite this article as: Fassbender *et al.*: TRIZol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis. *Reproductive Biology and Endocrinology* 2011 **9**:44.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

